Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Patients With Acute Hepatitis C (Study P03552 AM 2)
This study has been completed.
Sponsor:
Schering-Plough
Collaborator:
Biokos Farma srl
Information provided by (Responsible Party):
Schering-Plough
ClinicalTrials.gov Identifier:
NCT00686517
First received: May 27, 2008
Last updated: December 22, 2011
Last verified: December 2011
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this study is to evaluate the efficacy of three regimens of pegylated interferon-alfa 2b (PEG-IFN) either as monotherapy or in combination with ribavirin in participants with acute hepatitis C. After 12 weeks of observation from disease onset, participants will receive one of the following regimens: (1) a 24-week course of PEG-IFN monotherapy (PEG-IFN 24); or (2) a 12-week course of PEG-IFN monotherapy (PEG-IFN-12); or (3) a 12-week course of PEG-IFN in combination with ribavirin (PEG-IFN + RVB 12). After the treatment period, participants will enter a 12-month follow-up.
| Condition | Intervention | Phase |
|---|---|---|
|
Hepatitis C |
Biological: Pegylated interferon alfa-2b Drug: Ribavirin |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Open, Randomized, Multicentre Trial to Evaluate Efficacy and Safety of a 24-week Course of PEG-Interferon Alpha-2b Versus a 12-week Course of PEG-Interferon Alpha-2b Alone or Plus Ribavirin in Patients With Acute Hepatitis C |
Resource links provided by NLM:
Drug Information available for:
Interferon
Ribavirin
Interferon Alfa-2a
Interferon Alfa-2b
Peginterferon Alfa-2b
U.S. FDA Resources
Further study details as provided by Schering-Plough:
Primary Outcome Measures:
- Number of Participants With Sustained Response (SR) at the End of the 6-month Follow-up Period [ Time Frame: Evaluated at the end of 6 months ] [ Designated as safety issue: No ]SR was defined as serum Hepatitis C Virus (HCV RNA) level at the end of 6-month follow-up below 15 IU/mL.
Secondary Outcome Measures:
- Virologic Response at the End of Treatment Follow-up (ETR) [ Time Frame: At the end of treatment (either 12 weeks or 24 weeks depending on randomization). ] [ Designated as safety issue: No ]ETR was achieved if serum HCV RNA level at the end of 12 or 24 weeks treatment (depending on treatment arm) was <15 IU/mL.
- Virologic Response at 12 Months Post-treatment Follow-up (Long-term Response, [LTR]). [ Time Frame: At 12 months post-treatment (treatment period either 12 weeks or 24 weeks depending on randomization). ] [ Designated as safety issue: No ]LTR was obtained if serum HCV RNA level at the end of 12-month follow-up was <15 IU/mL.
- Number of Participants Presenting With Alanine Transferase (ALT) Level Normalization [ Time Frame: Evaluated at end of treatment (either 12 weeks or 24 weeks, depending on randomization), at 6-month follow-up visit, or at 12-month follow-up visit. ] [ Designated as safety issue: No ]ALT normalization was used as a measure of biochemical response to treatment. ALT levels were assessed at each study visit by the local laboratory, and efficacy measurements at the end of treatment, at 6 and 12 months post treatment follow-up were reported.
- Number of Participants With Rapid Virologic Response (RVR) [ Time Frame: Evaluated at 2 and 4 weeks of treatment ] [ Designated as safety issue: No ]Participants were considered to have RVR if serum HCV RNA level at 2 or 4 weeks of treatment was below the cut off value of the referring local laboratory of each participating site.
- Number of Peripheral Blood Mononuclear Cells (PBMCs) [ Time Frame: Treatment Weeks 2, 4, 8, and 12 ] [ Designated as safety issue: No ]Cellular Differentiation Cluster Antigen 8-Positive (CD8+) PBMCs were measured at randomization, Treatment Weeks 2, 4, 8, and 12.
| Enrollment: | 130 |
| Study Start Date: | December 2003 |
| Study Completion Date: | December 2010 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: PEG-IFN 24
pegylated interferon alpha-2b 1.5 ug/kg/week for 24 weeks
|
Biological: Pegylated interferon alfa-2b
1.5 ug/kg/week SC for 12 or 24 weeks
Other Name: SCH 54031, PegIntron
|
|
Experimental: PEG-IFN 12
pegylated interferon alpha-2b 1.5 ug/kg/week for 12 weeks
|
Biological: Pegylated interferon alfa-2b
1.5 ug/kg/week SC for 12 or 24 weeks
Other Name: SCH 54031, PegIntron
|
|
Experimental: PEG-IFN + RVB 12
pegylated interferon alpha-2b 1.5 ug/kg/week in combination with ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
|
Biological: Pegylated interferon alfa-2b
1.5 ug/kg/week SC for 12 or 24 weeks
Other Name: SCH 54031, PegIntron
Drug: Ribavirin
Ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
Other Name: SCH 18908, Rebetol
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Diagnosed with acute hepatitis C virus (HCV).
- Normal and Elevated serum alanine transferase (ALT) levels
- Positive serum HCV-RNA.
- Aged between 18 and 65 years.
- Negative urine or serum pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of the drug. Additionally, all fertile males with partners of childbearing age and females must be using reliable contraception during the study and additionally for participants treated with ribavirin, for 6 months (for woman) and 7 months (for man and his partner) after treatment completion
Exclusion Criteria:
- Liver disease unrelated to HCV infection
- Hemoglobin (Hgb) <12g/dL in women and <13g/dL in men; white blood cells (WBC) <3,000/uL; platelets (PLTs) <100,000/ul
- Women with ongoing pregnancy or who are breast feeding
- History of severe psychiatric disease, especially depression
- History of neurologic disease, especially epilepsy
- History or evidence of symptoms of severe cardiac, gastrointestinal and kidney disease
- Positive anti-Human Immunodeficiency Virus (HIV) antibodies
- Positive anti-nuclear antibodies (ANA) and/or Anti-Smooth Muscle Antibody (ASMA) (>1/80)
- Positive Hepatitis B surface antigen (HBsAg)
- History of having received any systemic anti-neoplastic or immunomodulatory treatment in the previous 6 months
- History or other evidence of severe illness or any other conditions which would make the participants, in the opinion of investigator, unsuitable for the study (active drug addict except those under methadone treatment, thalassemic, dyalized included)
Contacts and Locations
No Contacts or Locations Provided
More Information
No publications provided
| Responsible Party: | Schering-Plough |
| ClinicalTrials.gov Identifier: | NCT00686517 History of Changes |
| Other Study ID Numbers: | P03552 |
| Study First Received: | May 27, 2008 |
| Results First Received: | December 22, 2011 |
| Last Updated: | December 22, 2011 |
| Health Authority: | Italy: Ministry of Health |
Additional relevant MeSH terms:
|
Hepatitis Hepatitis A Hepatitis C Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections Flaviviridae Infections Interferon-alpha Interferon Alfa-2a Interferon Alfa-2b Interferons |
Ribavirin Peginterferon alfa-2b Reaferon Antiviral Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Immunologic Factors Physiological Effects of Drugs Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Growth Inhibitors Antineoplastic Agents Adjuvants, Immunologic |
ClinicalTrials.gov processed this record on June 18, 2013